[Federal Register: November 20, 2008 (Volume 73, Number 225)]
[Notices]
[Page 70404-70405]
[DOCID:fr20no08-113]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

[Docket No. FAA-2006-25709, Notice No. 93-87; Docket No. FAA-2008-0517,
Notice No. 08-05]

Congestion Management Rules for John F. Kennedy International
Airport, Newark Liberty International Airport, and LaGuardia Airport

AGENCY: Federal Aviation Administration.

ACTION: Notice of Slot Auction Bidder Seminar.

-----------------------------------------------------------------------

SUMMARY: This notice announces a Bidder Seminar for the 2009 New York
Slot Auctions, pursuant to the Federal Aviation Administration's
congestion management rules for John F. Kennedy International Airport,
Newark Liberty International Airport, and LaGuardia Airport (Final
Congestion Rules). [Docket No. FAA-2008-0517, Notice No. 08-05 and
Docket No. FAA-2006-25709, Notice No. 93-87].

DATES: The Slot Auction Bidder Seminar is scheduled for Friday,
December 5, 2008, from 8:30 a.m. to 1 p.m., Eastern Time.

ADDRESSES: The Slot Auction Bidder Seminar will be held at the Marriott
Crystal Gateway, 1700 Jefferson Davis Highway, Arlington, VA 22202 (in
Crystal City, 5-10 minutes from Washington Reagan National Airport).

For Further Information, to RSVP or to Contact the Agency Regarding the
Meeting:  Jeffrey Wharff, Office of Aviation Policy & Plans, Federal
Aviation Administration, 800 Independence Ave., SW., Washington, DC
20591; Phone<PHONE_NUMBER>; Fax:<PHONE_NUMBER>; E-mail:
<EMAIL_ADDRESS>    To Contact the Auction Manager Regarding the Seminar: Power
Auctions LLC, 1000 Potomac Street, NW., Washington, DC 20007; Phone
202-342-0909; Fax:<PHONE_NUMBER>; E-mail<EMAIL_ADDRESS>
Additional information about the auction can be found at: https://
www.slotauction.com/bidder-seminar.

SUPPLEMENTARY INFORMATION:
    The purpose of the Slot Auction Bidder Seminar is to provide
information to all interested parties concerning the congestion
management rules for LaGuardia, Kennedy and Newark Airports, what is
being auctioned, how an applicant can participate in the auctions, and
the associated schedule of events. It will also give attendees the
opportunity to ask questions. Key individuals from the Federal Aviation
Administration (FAA) and from Power Auctions LLC and Market Design Inc.
(PA/MDI), the auction manager, will speak at the seminar.
    The Bidder Seminar is open to carriers that currently have slots at
the three airports, other carriers that are interested in bidding, the
Port Authority of New York and New Jersey, and other government
agencies. Each organization should limit its participation to no more
than five individuals.
    A limited number of hotel rooms at the Marriott Crystal Gateway at
$189 per night (singles or doubles) have been reserved for the night of
December 4 for Bidder Seminar participants. Individuals should call the
hotel at<PHONE_NUMBER> and indicate that they are part of the ``FAA
Bidder Seminar'' group. The block of hotel rooms will be held only
until November 28 (or until the rooms are all reserved) and
participants are advised to book early to avoid disappointment.
    RSVPs for the Bidder Seminar are requested by November 28, 2008.
Space at the Bidder Seminar is limited so seats are only guaranteed to
those persons who RSVP.
    Persons with a disability requiring special accommodations, such as
an interpreter for the hearing impaired, should contact the FAA contact
noted above at least ten (10) calendar days prior to the meeting.
    A preliminary agenda is provided below. Information is also
available at https://www.slotauction.com/bidder-seminar.

----------------------------------------------------------------------------------------------------------------
                Time                                                     Item
----------------------------------------------------------------------------------------------------------------
 8-8:30 a.m........................   Registration
 8:30-8:50 a.m.....................   Introduction
                                     --Opening comments.
                                     --Background to the FAA Slot Auctions and rationale.
 8:50-9:15 a.m.....................   The Slots
                                     --Description of what is being offered in the Auctions (exact slot times
                                      will not be identified at this time).
                                     --Key parameters of the slots.
 9:15-10:40 a.m....................   The Auction and the Auction Manager
                                     --Background on PA/MDI and its role in the Auctions.
                                     --The auction methodology and rationale.
                                     --Determining the winners of slots.
                                     --Determining the prices paid for slots.
 10:40-11 a.m......................   Break
 11-11:30 a.m......................   The Auction Software System
                                     --How to bid in the Auction.
                                     --Overview of the Auction System.
                                     --System requirements to access the Auction System.
 11:30 a.m.-12 noon................   Process leading up to the Auctions and post-auction process
                                     --Key dates.
                                     --Submission of Expression of Interest.
                                     --Submission of bidder deposits.
                                     --Receipt of username and password.
                                     --Training: Mock auctions.

                                     --Live auction.
                                     --Post-auction process.
 12 noon-12:45 p.m.................   Q&A
 12:45-1:00 p.m....................   Closing comments, including:
                                     --Next steps.
                                     --Contact details for help-desk.
----------------------------------------------------------------------------------------------------------------

Robert Robeson,
Manager, Systems & Policy Analysis Division.
[FR Doc. E8-27593 Filed 11-19-08; 8:45 am]

BILLING CODE 4910-13-P


[Federal Register Volume 82, Number 116 (Monday, June 19, 2017)]
[Notices]
[Pages 27836-27838]
[FR Doc No: 2017-12620]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0015]

Agency Information Collection Activities; Proposed Collection;
Comment Request; Orphan Drugs; Common European Medicines Agency/Food
and Drug Administration Application Form for Orphan Drug Medicinal
Product Designation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on Common European Medicines
Agency (EMA)/FDA Application Form for Orphan Drug Medicinal Product
Designation (Form FDA 3671).

DATES: Submit either electronic or written comments on the collection
of information by August 18, 2017.

ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. Electronic comments
must be submitted on or before August 18, 2017. The https://www.regulations.gov electronic filing system will accept comments until
midnight Eastern Time at the end of August 18, 2017. Comments received
by mail/hand delivery/courier (for written/paper submissions) will be
considered timely if they are postmarked or the delivery service
acceptance receipt is on or before that date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2011-N-0015 for ``Orphan Drugs; Common EMA/FDA Application Form for
Orphan Medicinal Product Designation (Form FDA 3671)--21 CFR part
316.'' Received comments, those filed in a timely manner (see
ADDRESSES), will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://

www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A63, 11601
Landsdown St., North Bethesda, MD 20852<EMAIL_ADDRESS>301-796-
8867.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
    With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.

Orphan Drugs; Common EMA/FDA Application Form for Orphan Medicinal
Product Designation (Form FDA 3671) 21 CFR Part 316; OMB Control Number
0910-0167--Extension

    Sections 525 through 528 of the Federal Food, Drug, and Cosmetic
Act (the FD&C Act) (21 U.S.C. 360aa through 360dd) give FDA statutory
authority to do the following: (1) Provide recommendations on
investigations required for approval of marketing applications for
orphan drugs, (2) designate eligible drugs as orphan drugs, (3) set
forth conditions under which a sponsor of an approved orphan drug
obtains exclusive approval, and (4) encourage sponsors to make orphan
drugs available for treatment on an ``open protocol'' basis before the
drug has been approved for general marketing. The implementing
regulations for these statutory requirements have been codified under
part 316 (21 CFR part 316) and specify procedures that sponsors of
orphan drugs use in availing themselves of the incentives provided for
orphan drugs in the FD&C Act and sets forth procedures FDA will use in
administering the FD&C Act with regard to orphan drugs.
    Section 316.10 specifies the content and format of a request for
written recommendations concerning the nonclinical laboratory studies
and clinical investigations necessary for approval of marketing
applications. Section 316.12 provides that, before providing such
recommendations, FDA may require results of studies to be submitted for
review. Section 316.14 contains provisions permitting FDA to refuse to
provide written recommendations under certain circumstances. Within 90
days of any refusal, a sponsor may submit additional information
specified by FDA. Based on past experience, FDA estimates that there
will be one respondent to Sec. Sec.  316.10, 316.12, and 316.14
requiring 50 hours of human resources annually.
    Section 316.20 specifies the content and format of an orphan drug
application which includes requirements that an applicant document that
the disease is rare (affects fewer than 200,000 persons in the United
States annually) or that the sponsor of the drug has no reasonable
expectation of recovering costs of research and development of the
drug. Section 316.21 specifies content of a request for orphan drug
designation required for verification of orphan-drug status. Section
316.26 allows an applicant to amend the applications under certain
circumstances. Based on past experience, FDA estimates 496 respondents
to Sec. Sec.  316.20, 316.21 and 316.26, requiring 93,000 hours of
human resources annually.
    The Common EMA/FDA Application Form for Orphan Medicinal Product
Designation (Form FDA 3671) is intended to benefit sponsors who desire
to seek orphan designation of drugs intended for rare diseases or
conditions from both the European Commission and FDA by reducing the
burden of preparing separate applications to meet the regulatory
requirements in each jurisdiction. It highlights the regulatory
cooperation between the United States and the European Union mandated
by the Transatlantic Economic Council (TEC). Based on past experience,
FDA estimates there will be 60 respondents using the form requiring 450
hours of human resources annually.
    Section 316.22 specifies requirement of a permanent resident agent
for foreign sponsors. Based on past experience, FDA estimates 70
respondents requiring 140 hours of human resources annually. Section
316.24(a) specifies a requirement that sponsors respond to deficiency
letters from FDA on designation requests within 1 year of issuance of
the deficiency letter, unless within that time frame, the sponsor
requests an extension of time to respond. Based on past experience, FDA
estimates 20 respondents requiring 40 hours of human resources
annually.
    Section 316.27 specifies content of a change in ownership of
orphan-drug designation. Based on past experience, FDA estimates 63
respondents requiring 315 hours of human resources annually. Section
316.30 requires submission of annual reports, including progress
reports on studies, a description of the investigational plan, and a
discussion of changes that may affect orphan status. Based on number of
orphan-drug designations, the number of respondents is estimated as 744
requiring 2,232 hours of human resources annually. Finally, Sec.
316.36 describes information required of sponsor when there is
insufficient quantity of approved orphan drug. Based on past
experience, FDA estimates two respondents requiring 90 hours of human
resources annually.
    The information requested will provide the basis for an FDA
determination that the drug is for a rare disease or condition and
satisfies the requirements for obtaining orphan drug status. Secondly,
the information will describe the medical and regulatory history of the
drug. The respondents to this collection of information are
biotechnology firms, drug companies, and academic clinical researchers.
    FDA estimates the burden of this collection of information as
follows:

                                 Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
                                                      Annual
         21 CFR section              Number of    frequency  per   Total annual      Hours per      Total hours
                                    respondents      response        responses       response
----------------------------------------------------------------------------------------------------------------
Content and format when seeking                1               1               1              50              50
 written recommendations;
 results of studies; amendments
 (316.10, 316.12 & 316.14)......
Content and format of a request              496            1.25             620             150          93,000
 for orphan-drug designation;                 60             1.5              90               5             450
 request for verification of
 orphan-drug status; amendments
 (316.20, 316.21 & 316.26) FDA
 Form 3671......................
Notifications of changes in                   70               1              70               2             140
 agents (316.22)................
Deficiency letters and granting               20               1              20               2              40
 orphan-drug designation
 (316.24(a))....................
Submissions to change ownership               63               1              63               5             315
 of orphan-drug designation
 (316.27).......................
Annual reports (316.30).........             744               1             744               3           2,232
Assurance of the availability of               2               3               6              15              90
 sufficient quantities of the
 orphan drug; holder's consent
 for the approval of other
 marketing applications for the
 same drug (316.36).............
                                 -------------------------------------------------------------------------------
    Total.......................  ..............  ..............  ..............  ..............          96,317
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
  information.

    FDA has experienced increases in: (1) The number of submissions to
change ownership of orphan-drug designation (21 CFR 316.27), (2) the
number of annual reports 21 CFR 316.30, and (3) assurances of the
availability of sufficient quantities of the orphan drug and the
holder's consent for the approval of other marketing applications for
the same drug (21 CFR 316.36). In contrast, however, the use of Form
FDA 3671, the application form to submit for product designation to the
European Medicines Agency and to the FDA Office of Orphan Products, has
decreased from 6,760 to 450 total burden hours.

    Dated: June 13, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-12620 Filed 6-16-17; 8:45 am]
 BILLING CODE 4164-01-P


[Federal Register Volume 87, Number 240 (Thursday, December 15, 2022)]
[Notices]
[Pages 76617-76619]
[FR Doc No: 2022-27199]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Combined Notice of Filings #1

    Take notice that the Commission received the following exempt
wholesale generator filings:

    Docket Numbers: EG23-29-000.
    Applicants: Moss Landing Energy Storage 3, LLC, Vistra Corp.
    Description: Moss Landing Energy Storage 3, LLC et. al. submits
Notice of Self-Certification of Exempt Wholesale Generator Status.
    Filed Date: 12/8/22.
    Accession Number: 20221208-5216.
    Comment Date: 5 p.m. ET 12/29/22.

    Take notice that the Commission received the following Complaints
and Compliance filings in EL Dockets:

    Docket Numbers: EL23-14-000.
    Applicants: Alternative Transmission Inc.
    Description: Petition for Declaratory Order of [Alternative
Transmission Inc.].
    Filed Date: 12/9/22.
    Accession Number: 20221209-5093.
    Comment Date: 5 p.m. ET 12/30/22.

    Take notice that the Commission received the following electric
rate filings:

    Docket Numbers: ER10-3177-002; ER10-3181-005; ER10-3285-004; ER17-
991-009.

    Applicants: Hunlock Energy, LLC, UGI Utilities Inc., UGI
Development Company, UGI Energy Services, Inc.
    Description: Triennial Market Power Analysis for Northeast Region
and Notice of Change in Status of UGI Energy Services, LLC, et al.
    Filed Date: 12/8/22.
    Accession Number: 20221208-5218.
    Comment Date: 5 p.m. ET 2/6/23.

    Docket Numbers: ER22-26-003.
    Applicants: PJM Interconnection, L.L.C.
    Description: Compliance filing: Compliance Filing to Nov. 9, 2022
Order Approving Settlement in ER22-26 to be effective 2/1/2023.
    Filed Date: 12/8/22.
    Accession Number: 20221208-5111.
    Comment Date: 5 p.m. ET 12/29/22.

    Docket Numbers: ER22-2158-002.
    Applicants: Public Service Company of New Mexico.
    Description: Compliance filing: Compliance Filing Re November 8,
2022 Order to be effective 6/22/2022.
    Filed Date: 12/8/22.
    Accession Number: 20221208-5120.
    Comment Date: 5 p.m. ET 12/29/22.

    Docket Numbers: ER23-72-001.
    Applicants: Omaha Public Power District, Southwest Power Pool, Inc.
    Description: Tariff Amendment: Omaha Public Power District submits
tariff filing per 35.17(b): Omaha Public Power District Amended
Revisions to Formula Rate Protocols to be effective 2/8/2023.
    Filed Date: 12/9/22.
    Accession Number: 20221209-5017.
    Comment Date: 5 p.m. ET 12/30/22.

    Docket Numbers: ER23-582-000.
    Applicants: Northern States Power Company, a Minnesota corporation.
    Description: Sec.  205(d) Rate Filing: 2022-12-08 GRE FSA Eidswold
Sub 717-NSP to be effective 12/9/2022.
    Filed Date: 12/8/22.
    Accession Number: 20221208-5113.
    Comment Date: 5 p.m. ET 12/29/22.

    Docket Numbers: ER23-583-000.
    Applicants: PJM Interconnection, L.L.C.
    Description: Sec.  205(d) Rate Filing: Original NSA, Service
Agreement No. 6605; Queue No. AB1-056 (correction) to be effective 8/
16/2022.
    Filed Date: 12/9/22.
    Accession Number: 20221209-5027.
    Comment Date: 5 p.m. ET 12/30/22.

    Docket Numbers: ER23-584-000.
    Applicants: PJM Interconnection, L.L.C.
    Description: Tariff Amendment: Notice of Cancellation of ICSA, SA
No. 4220; Queue No. AA1-034 to be effective 9/16/2022.
    Filed Date: 12/9/22.
    Accession Number: 20221209-5031.
    Comment Date: 5 p.m. ET 12/30/22.

    Docket Numbers: ER23-585-000.
    Applicants: Virginia Electric and Power Company, PJM
Interconnection, L.L.C.
    Description: Sec.  205(d) Rate Filing: Virginia Electric and Power
Company submits tariff filing per 35.13(a)(2)(iii: Dominion submits One
WDSA, SA No. 6524 to be effective 12/1/2022.
    Filed Date: 12/9/22.
    Accession Number: 20221209-5034.
    Comment Date: 5 p.m. ET 12/30/22.

    Docket Numbers: ER23-586-000.
    Applicants: Midcontinent Independent System Operator, Inc.
    Description: Sec.  205(d) Rate Filing: 2022-12-09_SA 3379 NIPSCO-
Meadow Lake Solar Park 1st Rev GIA (J913) to be effective 12/2/2022.
    Filed Date: 12/9/22.
    Accession Number: 20221209-5039.
    Comment Date: 5 p.m. ET 12/30/22.

    Docket Numbers: ER23-587-000.
    Applicants: Southwest Power Pool, Inc.
    Description: Sec.  205(d) Rate Filing: Revisions to Update the
Available Flowgate Capability Calculation Process to be effective 2/21/
2023.
    Filed Date: 12/9/22.
    Accession Number: 20221209-5051.
    Comment Date: 5 p.m. ET 12/30/22.

    Docket Numbers: ER23-588-000.
    Applicants: Alabama Power Company.
    Description: Sec.  205(d) Rate Filing: Southeast EEM Agreement
Amendment Filing (Exhibit A Revisions) to be effective 1/1/2023.
    Filed Date: 12/9/22.
    Accession Number: 20221209-5054.
    Comment Date: 5 p.m. ET 12/30/22.

    Docket Numbers: ER23-589-000.
    Applicants: PJM Interconnection, L.L.C.
    Description: Sec.  205(d) Rate Filing: Amendment to ISA, Service
Agreement No. 4322; Queue No. Z1-036 to be effective 12/3/2015.
    Filed Date: 12/9/22.
    Accession Number: 20221209-5063.
    Comment Date: 5 p.m. ET 12/30/22.

    Docket Numbers: ER23-590-000.
    Applicants: Chaves County Solar II, LLC.
    Description: Baseline eTariff Filing: Chaves County Solar II, LLC
Application for Market-Based Rate Authority to be effective 2/8/2023.
    Filed Date: 12/9/22.
    Accession Number: 20221209-5091.
    Comment Date: 5 p.m. ET 12/30/22.

    Docket Numbers: ER23-592-000.
    Applicants: PJM Interconnection, L.L.C.
    Description: Sec.  205(d) Rate Filing: Original WMPA, Service
Agreement No. 6731; Queue No. AE2-248 to be effective 11/9/2022.
    Filed Date: 12/9/22.
    Accession Number: 20221209-5117.
    Comment Date: 5 p.m. ET 12/30/22.

    Docket Numbers: ER23-593-000.
    Applicants: PJM Interconnection, L.L.C.
    Description: Sec.  205(d) Rate Filing: PJM submits Amended NJ State
Agreement Approach Study Agreement, SA No. 5890 to be effective 11/18/
2020.
    Filed Date: 12/9/22.
    Accession Number: 20221209-5118.
    Comment Date: 5 p.m. ET 12/30/22.

    Docket Numbers: ER23-594-000.
    Applicants: Massachusetts Electric Company.
    Description: Tariff Amendment: 2022-12-09 Notice of Cancellation of
Service Agreement No. IA-MECO-28-01 to be effective 2/8/2023.
    Filed Date: 12/9/22.
    Accession Number: 20221209-5147.
    Comment Date: 5 p.m. ET 12/30/22.

    Docket Numbers: ER23-595-000.
    Applicants: Pacific Gas and Electric Company.
    Description: Sec.  205(d) Rate Filing: Transmission Access Charge
Balancing Account Adjustment (TACBAA) 2023 to be effective 3/1/2023.
    Filed Date: 12/9/22.
    Accession Number: 20221209-5153.
    Comment Date: 5 p.m. ET 12/30/22.

    Docket Numbers: ER23-596-000.
    Applicants: Duke Energy Florida, LLC.
    Description: Sec.  205(d) Rate Filing: DEF-Shady Hills--Amended and
Restated LGIA SA No. 230 to be effective 12/3/2022.
    Filed Date: 12/9/22.
    Accession Number: 20221209-5154.
    Comment Date: 5 p.m. ET 12/30/22.

    The filings are accessible in the Commission's eLibrary system
(https://elibrary.ferc.gov/idmws/search/fercgensearch.asp) by querying
the docket number.
    Any person desiring to intervene or protest in any of the above
proceedings must file in accordance with Rules 211 and 214 of the
Commission's Regulations (18 CFR 385.211 and 385.214) on or before 5:00
p.m. Eastern time on the specified comment date. Protests may be
considered, but intervention is necessary to become a party to the
proceeding.
    eFiling is encouraged. More detailed information relating to filing
requirements, interventions, protests, service, and qualifying
facilities filings can be found at: http://www.ferc.gov/docs-filing/efiling/filing-req.pdf. For

other information, call<PHONE_NUMBER> (toll free). For TTY, call (202)
502-8659.

    Dated: December 9, 2022.
Debbie-Anne A. Reese,
Deputy Secretary.
[FR Doc. 2022-27199 Filed 12-14-22; 8:45 am]
BILLING CODE 6717-01-P